Table 1.
Clinical factor | Cases(n = 143) | CLCA2expression | P value | |
---|---|---|---|---|
Low | High | |||
Gendar | ||||
Male | 104 | 53 | 51 | 0.759 |
Female | 39 | 21 | 18 | |
Ages | ||||
< 45 | 76 | 41 | 35 | 0.575 |
≥ 45 | 67 | 33 | 34 | |
T stage | ||||
T1-2 | 35 | 18 | 17 | 0.965 |
T3-4 | 108 | 56 | 52 | |
N stage | ||||
N0-1 | 79 | 42 | 37 | 0.706 |
N2-3 | 64 | 32 | 32 | |
Clinical stage | ||||
I-II | 12 | 5 | 7 | 0.465 |
III-IV | 131 | 69 | 62 | |
WHO histological classification | ||||
Differentiated non-keratinized (type 2) | 3 | 1 | 2 | 0.03 |
Undifferentiated or Poorly Differentiated (type 3) | 140 | 73 | 67 | |
Local-regional relapse | ||||
NO | 123 | 63 | 60 | 0.754 |
YES | 20 | 11 | 9 | |
Diatant metastasis | ||||
NO | 124 | 60 | 64 | 0.04 |
YES | 19 | 14 | 5 | |
Progression | ||||
NO | 107 | 50 | 57 | 0.038 |
YES | 36 | 24 | 12 | |
Death | ||||
NO | 114 | 54 | 60 | 0.038 |
YES | 29 | 20 | 9 |
Abbreviations: WHO World Health Organization,OS overall survival, DMFS distant metastasis-free survival, CI confidence interval, HR hazard ratio. Statistical significance (p < 0.05) is shown in bold